登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H34O2
化学文摘社编号:
分子量:
330.50
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
SMILES string
O(CC)C(=O)\C=C\C=C\C=C\C=C\C=C\CCCCCCCCC
InChI
1S/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h12-21H,3-11H2,1-2H3/b13-12+,15-14+,17-16+,19-18+,21-20+
InChI key
DTEMJWLYSQBXEL-MBFZXKRTSA-N
grade
pharmaceutical primary standard
API family
eicosapentaenoic acid
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
shipped in
wet ice
storage temp.
−20°C
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Eicosapentaenoic acid ethyl ester EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Christie M Ballantyne et al.
The American journal of cardiology, 110(7), 984-992 (2012-07-24)
AMR101 is an ω-3 fatty acid agent containing ≥96% pure icosapent-ethyl, the ethyl ester of eicosapentaenoic acid. The efficacy and safety of AMR101 were evaluated in this phase 3, multicenter, placebo-controlled, randomized, double-blinded, 12-week clinical trial (ANCHOR) in high-risk statin-treated
Abbie L Cawood et al.
Atherosclerosis, 212(1), 252-259 (2010-06-15)
To examine n-3 polyunsaturated fatty acid (PUFA) incorporation into atherosclerotic plaques and the association with plaque inflammation and stability. Patients awaiting carotid endarterectomy (n=121) were randomised to consume control capsules or n-3 PUFA ethyl ester capsules until surgery (median 21
Eun Young Park et al.
Journal of agricultural and food chemistry, 53(21), 8334-8341 (2005-10-13)
The effects of the addition of amino acids and peptides on the oxidation of eicosapentaenoic acid ethyl ester (EPE) encapsulated by maltodextrin (MD) were investigated. The encapsulated lipid was prepared in two steps, that is, by mixing of EPE with
Terry A Jacobson
Expert review of cardiovascular therapy, 10(6), 687-695 (2012-08-17)
ω-3 fatty acids reduce triglyceride (TG) levels, but corresponding increases in low-density lipoprotein cholesterol (LDL-C) levels may compromise achievement of lipid goals in patients with elevated cardiovascular risk. AMR101 is an investigational agent containing ≥96% of pure icosapent ethyl (the
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.
Antonis Zampelas
Atherosclerosis, 212(1), 34-35 (2010-07-20)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持